President The Stock Exchange of Thailand The Company wishes to present the Management Discussion & Analysis (MD&A) on the operating and financial status for the 2nd quarter of 2018. The MD&A would enable the
The Stock Exchange of Thailand The Company wishes to present the Management Discussion & Analysis (MD&A) on the operating and financial status for the 1st quarter of 2020. The MD&A would enable the
a result the company has a higher gross margin from the same period last year. 2. Sales cost to revenue ratio decreased by 10.12% (from 94.14% in 2019 to 84.02% in 2020) due to production efficiency
is an increase in raw material creditor amount of Baht 25.83 million ,due to the fact that the company has a rising sale trend, so it has to order more raw material. 2.2 Non current liability as at
/2561 June 19, 2018 Subject: Management’s discussion and analysis of the Company’s operating results for Q1/2018 period To: President The Stock Exchange of Thailand DOD Biotech Public Company Limited
) Public Company Limited ( the “Company”) would like to clarify its operation results for the Quarter2/FY2020 (ended March 31st, 2020) of the Company and its subsidiaries, as follows: (unit: million baht) Q2
2018, the Company had gain on exchange rate of THB 18.58 million. Cost of Sales and Gross Profit The Company’s cost of sales is mainly consisted of raw material cost which is equal to approximately 85
sales volume. And higher raw material costs. 3. The increase in selling and administrative expenses was 11.79% compared to the same period last year. As of June 30, 2017, the Company has adjusted its
24 มิถุนายน 2540 บริษัท จี เจ สตลี จ ำกดั (มหำชน) G J Steel Public Company Limited ทะเบียนเลขท่ี 0107538000401 ส านกังานใหญ่ : เลขท่ี 88 ปาโซ่ ทาวเวอร์ ชั้น 24 ถนนสีลม แขวงสุริยวงศ ์เขตบางรัก